Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203021 · ClinicalTrials.gov registry record · Phase 4
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
A Phase 4 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 208
- Enrollment target
NCT00203021 is a Phase 4 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 208 participants.
The verdict
NCT00203021, a Phase 4 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 208 participants
- Enrollment target
Study Summary
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.
Interventions
- DRUG Glatiramer acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 1994-03-26 |
| Est. Completion | 2018-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203021
The ClinicalTrials.gov registry entry for NCT00203021 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glatiramer acetate is the first listed.
NCT00203021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203021 about?
NCT00203021 is a clinical study titled "Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness". This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multipl...
What is the current status of trial NCT00203021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 208 participants. The study started on 1994-03-26. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT00203021?
The interventions under investigation include: Glatiramer acetate (DRUG).
Who is sponsoring clinical trial NCT00203021?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.